Tumorigenesis and phenotypic characteristics of mucin-producing bile duct tumors: an immunohistochemical approach
暂无分享,去创建一个
Yasunori Sato | Y. Nakanuma | K. Harada | M. Sasaki | H. Ikeda | Y. Zen | T. Uehara
[1] Y. Nakanuma,et al. Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm. , 2008, Human pathology.
[2] Y. Nakanuma,et al. Over‐expression of polycomb group protein EZH2 relates to decreased expression of p16INK4a in cholangiocarcinogenesis in hepatolithiasis , 2008, The Journal of pathology.
[3] D. Katzka,et al. Electronic Clinical Challenges and Images in GI , 2006 .
[4] Herng‐Sheng Lee,et al. Electronic clinical challenges and images in GI. Noninvasive and minimally invasive papillary carcinomas of the common bile duct. , 2008, Gastroenterology.
[5] Y. Nimura,et al. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[6] Y. Nakanuma,et al. Expression profiles of MUC mucins and trefoil factor family (TFF) peptides in the intrahepatic biliary system: physiological distribution and pathological significance. , 2007, Progress in histochemistry and cytochemistry.
[7] Y. Atomi,et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria , 2007, Modern Pathology.
[8] L. Roberts,et al. An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. , 2007, Human pathology.
[9] Y. Nakanuma,et al. Intraductal papillary cholangiocarcinoma and atypical biliary epithelial lesions confused with intrabiliary extension of metastatic colorectal carcinoma. , 2007, Hepato-gastroenterology.
[10] M. Mino‐Kenudson,et al. Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas: Its Histopathologic Difference Between 2 Major Types , 2006, The American journal of surgical pathology.
[11] Y. Nakanuma,et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas , 2006, Hepatology.
[12] Y. Nakanuma,et al. Biliary cystic tumors with bile duct communication: a cystic variant of intraductal papillary neoplasm of the bile duct , 2006, Modern Pathology.
[13] P. Pisters,et al. Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2006, Medical Principles and Practice.
[14] Y. Nakanuma,et al. Multicystic biliary hamartoma: a hitherto undescribed lesion. , 2006, Human pathology.
[15] Y. Jan,et al. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct--an immunohistochemical study of 110 cases of hepatolithiasis. , 2006, Journal of hepatology.
[16] K. Arihiro,et al. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. , 2005, International journal of oncology.
[17] M. Nagino,et al. Aberrant expression of pyloric gland‐type mucin in mucin‐producing bile duct carcinomas: A clear difference between the core peptide and the carbohydrate moiety , 2005, Pathology international.
[18] L. Ben-Porat,et al. Papillary Phenotype Confers Improved Survival After Resection of Hilar Cholangiocarcinoma , 2005, Annals of surgery.
[19] Y. Nakanuma,et al. Intrahepatic cholangiocarcinoma with multicystic, mucinous appearance and oncocytic change , 2005, Pathology international.
[20] D. Berry,et al. Changes in the Wnt signalling pathway in gastrointestinal cancers and their prognostic significance. , 2005, European journal of cancer.
[21] Y. Nimura,et al. Frequent p16ink4a inactivation is an early and frequent event of intraductal papillary neoplasm of the liver arising in hepatolithiasis. , 2004, Human pathology.
[22] Y. Jan,et al. Aberrant expression of CDX2 is closely related to the intestinal metaplasia and MUC2 expression in intraductal papillary neoplasm of the liver in hepatolithiasis , 2004, Laboratory Investigation.
[23] E. Yu,et al. Clinicopathologic review of 58 patients with biliary papillomatosis , 2004, Cancer.
[24] A. Poustka,et al. Site‐characteristic expression and induction of trefoil factor family 1, 2 and 3 and malignant brain tumor‐1 in normal and diseased intrahepatic bile ducts relates to biliary pathophysiology , 2004, Liver international : official journal of the International Association for the Study of the Liver.
[25] E. Furth,et al. Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract. , 2003, Human pathology.
[26] K. Kawachi,et al. Hepatobiliary cystadenocarcinoma connected to the hepatic duct: a case report and review of the literature. , 2003, Hepato-gastroenterology.
[27] E. Furth,et al. Microsatellite Instability in Intraductal Papillary Neoplasms of the Biliary Tract , 2002, Modern Pathology.
[28] M. Miyazaki,et al. Cholangiocarcinoma: Recent progress. Part 2: Molecular pathology and treatment , 2002, Journal of gastroenterology and hepatology.
[29] F. Sarkar,et al. The Dichotomy in the Preinvasive Neoplasia to Invasive Carcinoma Sequence in the Pancreas: Differential Expression of MUC1 and MUC2 Supports the Existence of Two Separate Pathways of Carcinogenesis , 2002, Modern Pathology.
[30] S. Kawasaki,et al. Matrix metalloproteinase‐7 expression and biologic aggressiveness of cholangiocellular carcinoma , 2002, Cancer.
[31] K. Tsuneyama,et al. Oncocytic Biliary Cystadenocarcinoma Is a Form of Intraductal Oncocytic Papillary Neoplasm of the Liver , 2001, Modern Pathology.
[32] Y. Jan,et al. Intraductal papillary neoplasia of the liver associated with hepatolithiasis , 2001, Hepatology.
[33] S. Satoh,et al. Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma. , 2001, Journal of hepatology.
[34] K. Tsuneyama,et al. Expression of MUC1 and MUC2 and carbohydrate antigen Tn change during malignant transformation of biliary papillomatosis , 2001, Histopathology.
[35] D. Henson,et al. Noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts , 2000, Cancer.
[36] M. Nagino,et al. Treatment Strategy for Mucin-producing Intrahepatic Cholangiocarcinoma: Value of Percutaneous Transhepatic Biliary Drainage and Cholangioscopy , 1999, World Journal of Surgery.
[37] S. Tsao,et al. Downregulation and abnormal expression of E-cadherin and beta-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. , 1999, Human pathology.
[38] A. Sparks,et al. Identification of c-MYC as a target of the APC pathway. , 1998, Science.
[39] T. Terada,et al. Expression of e‐cadherin, α‐catenin, β‐catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: An immunohistochemical study , 1998 .
[40] Y. Nakanuma,et al. Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply , 1997, Microscopy research and technique.
[41] Y. Kim,et al. Characterization of apomucin expression in intrahepatic cholangiocarcinomas and their precursor lesions: An immunohistochemical study , 1996, Hepatology.
[42] Y. Okada,et al. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors , 1996, Hepatology.
[43] T. Terada,et al. Expression of pancreatic enzymes (alpha-amylase, trypsinogen, and lipase) during human liver development and maturation. , 1995, Gastroenterology.
[44] K. Ishak,et al. Hepatobiliary Cystadenoma and Cystadenocarcinoma: A Light Microscopic and Immunohistochemical Study of 70 Patients , 1994, The American journal of surgical pathology.
[45] T. Terada,et al. Intrahepatic peribiliary glands of humans. II. Pathological spectrum , 1994, Journal of gastroenterology and hepatology.
[46] T. Terada,et al. Development of human intrahepatic peribiliary glands. Histological, keratin immunohistochemical, and mucus histochemical analyses. , 1993, Laboratory investigation; a journal of technical methods and pathology.
[47] T. Terada,et al. Pathologic observations of intrahepatic peribiliary glands in 1,000 consecutive autopsy livers: IV. Hyperplasia of intramural and extramural glands. , 1992, Human pathology.
[48] A. Agildere,et al. Biliary cystadenoma and cystadenocarcinoma. , 1991, AJR. American journal of roentgenology.
[49] T. Terada,et al. Pathological observations of intrahepatic peribiliary glands in 1,000 consecutive autopsy livers. II. A possible source of cholangiocarcinoma , 1990, Hepatology.
[50] T. Terada,et al. Pathologic observations of intrahepatic peribiliary glands in 1000 consecutive autopsy livers. Heterotopic pancreas in the liver. , 1990, Gastroenterology.
[51] Nagorney Dm,et al. Carcinoma of the gallbladder and extrahepatic bile ducts. , 1988 .
[52] H. Edmondson,et al. Cystadenoma with mesenchymal stroma (CMS) in the liver and bile ducts. A clinicopathologic study of 17 cases, 4 with malignant change , 1985, Cancer.
[53] W. Ewig. [Diseases of the bile ducts]. , 1961, Hippokrates.
[54] T. Suga,et al. [Mucinous cystic neoplasm of the pancreas]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.
[55] Y. Nakanuma,et al. Biliary papillary neoplasm of the liver. , 2002, Histology and histopathology.
[56] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[57] Stanley R. Hamilton,et al. Pathology and genetics of tumours of the digestive system , 2000 .
[58] S. Thung,et al. Diffuse hyperplasia of the peribiliary glands. , 1998, Archives of pathology & laboratory medicine.
[59] T. Terada,et al. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. , 1998, Hepatology.
[60] D. Nagorney,et al. Carcinoma of the gallbladder and extrahepatic bile ducts. , 1988, Seminars in oncology.